tiprankstipranks
Advertisement
Advertisement
ProMIS Neurosciences’ PMN310 shows positive result in Alzheimer’s Phase 1b trial
PremiumThe FlyProMIS Neurosciences’ PMN310 shows positive result in Alzheimer’s Phase 1b trial
6d ago
ProMIS Neurosciences initiated with a Buy at Chardan
Premium
The Fly
ProMIS Neurosciences initiated with a Buy at Chardan
7d ago
Buy Rating Reiterated on PMN310’s Promising Phase 1a Data and Unchanged $18 Price Target
Premium
Ratings
Buy Rating Reiterated on PMN310’s Promising Phase 1a Data and Unchanged $18 Price Target
19d ago
Analyst Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price Target on Differentiated Alzheimer’s Candidate PMN310
PremiumRatingsAnalyst Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price Target on Differentiated Alzheimer’s Candidate PMN310
1M ago
Ram Selvaraju Reiterates Buy on ProMIS Neurosciences, Maintains $18 12-Month Price Target on Differentiated PMN310 Alzheimer’s Profile
Premium
Ratings
Ram Selvaraju Reiterates Buy on ProMIS Neurosciences, Maintains $18 12-Month Price Target on Differentiated PMN310 Alzheimer’s Profile
2M ago
ProMIS Neurosciences shareholders approve directors and incentive plan
Premium
Company Announcements
ProMIS Neurosciences shareholders approve directors and incentive plan
2M ago
ProMIS Neurosciences files to sell 13.83M common shares for holders
PremiumThe FlyProMIS Neurosciences files to sell 13.83M common shares for holders
5M ago
Promis Neurosciences Inc trading resumes
Premium
The Fly
Promis Neurosciences Inc trading resumes
6M ago
Promis Neurosciences Inc trading halted, volatility trading pause
Premium
The Fly
Promis Neurosciences Inc trading halted, volatility trading pause
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100